Published | Last updated
What the IRB Approval Process Involves Under the Common Rule
An institutional review board (IRB) has the authority to approve research, require modifications to secure approval, or disapprove it.8 The policy applies to human subjects research conducted or supported by a federal department or agency that has adopted it, and it does not override state, local or foreign laws that add protections.5 The regulation defines research as a systematic investigation designed to develop or contribute to generalizable knowledge,9 so the first question is whether your project is research at all. Patel and colleagues contrast research with quality improvement, which aims at immediate change in how care is delivered.7
To approve a study, the IRB must find, among other things, that risks are minimized, that risks are reasonable in relation to anticipated benefits, that selection of subjects is equitable, that informed consent is sought and documented or appropriately waived, and, when appropriate, that data monitoring and protection of privacy and confidentiality are adequate.10 When subjects are likely to be vulnerable to coercion or undue influence, such as children, prisoners, people with impaired decision-making capacity or economically or educationally disadvantaged persons, the study must include additional safeguards.10
Exempt, Expedited or Full Board: Which Review Route Applies?
The table sets out what each route means under the regulation. Each cell carries the section it comes from.
| Route | Who reviews | What qualifies | Continuing review |
|---|---|---|---|
| Exempt | No full review; limited IRB review can or must apply under 46.104(d)(2)(iii), (d)(3)(i)(C), (d)(7) and (d)(8)1,8 | Only involvement of human subjects is in one of eight listed categories1 | Not required for exempt research with limited IRB review, unless the IRB determines otherwise8 |
| Expedited | IRB chairperson or experienced reviewers the chair designates; they may not disapprove2 | Research on the HHS list with no more than minimal risk, minor changes to approved research, and research for which limited IRB review is a condition of exemption2 | Not required unless the IRB determines otherwise8 |
| Full board | Convened meeting with a majority of members present, including one whose primary concerns are non-scientific3 | Reviewed at a convened meeting whenever the expedited procedure is not used3 | At intervals suited to the risk and at least once a year, except as 46.109(f) allows8 |
Swipe sideways to see every column.
The eight exempt categories
Exemption is a list of categories, and a study must meet the conditions of its category.1
- Normal educational practices in established educational settings.1
- Educational tests, surveys, interviews and observation of public behavior, if identifiers are not readily ascertainable, disclosure would not place subjects at risk, or an IRB conducts limited review.
- Benign behavioral interventions with adults who agree in advance, under the same identifiability criteria.
- Secondary research with identifiable private information or biospecimens when consent is not required and a listed condition is met.
- Research and demonstration projects on public benefit or service programs run or supported by a federal agency.
- Taste and food quality evaluation and consumer acceptance studies under stated food-safety conditions.
- Storage or maintenance of identifiable information or biospecimens for secondary research when broad consent is required and an IRB conducts limited review.
- Secondary research under broad consent when an IRB conducts limited review and the study stays within the scope of that consent.
Children, prisoners and the exemption categories
Exemption is narrower for some populations. For research with children, the exemptions for educational settings, secondary research, public benefit programs, taste tests and broad-consent storage and use may be applied if their conditions are met, but the survey, interview and educational test exemptions apply only to educational tests or observation of public behavior in which the investigators do not participate, and the limited-review variant may not be applied. For research with prisoners, the exemptions do not apply, except for research aimed at a broader population that only incidentally includes prisoners.1
The nine expedited categories
The HHS list that the regulation refers to has nine categories: clinical studies of drugs and devices that need no investigational application or exemption; blood sampling within set limits; noninvasive collection of biological specimens; noninvasive clinical data collection; research on materials collected for nonresearch purposes; voice, video, digital or image recordings made for research; research on individual or group characteristics or behavior, including surveys, interviews, oral history, focus groups, program evaluation and quality assurance methods; and two categories of continuing review.11,2 The list states that being on it does not make an activity minimal risk, and that the expedited procedure may not be used where identification of subjects or their responses would reasonably place them at risk of criminal or civil liability or be damaging to their financial standing, employability, insurability or reputation, or be stigmatizing, unless reasonable and appropriate protections keep risks of invasion of privacy and breach of confidentiality no greater than minimal.11 The standard consent requirements apply whichever route is used.11
How Long Does IRB Approval Take? Evidence From Two Open-Access Studies
Two CC BY papers report real timings for one study each. Editverse redrew their numbers in R and computed the ratios and shares shown.6,7
Sixteen Canadian hospitals, one database study
Ezzat and colleagues followed the ethics applications of the Canadian Perinatal Network at 16 tertiary hospitals between 2005 and 2008. In Canada the reviewing body is a research ethics board (REB), the counterpart of a US IRB. The median time to an initial response from the board was 31 days (range 2 to 174) and to final approval 42 days (range 4 to 443).6 Where the board asked for more information (6 boards), the median was 178 days; where it raised no issues (10 boards), 33 days. The first is 5.4 times the second.6

Privacy and consent were the two major issues the boards raised, and every hospital used a different application form.6 Nine sites handled the application as expedited review, with a median of 33 days (range 8 to 239).6
Fourteen US hospitals, one improvement study
Patel and colleagues tracked a multisite study of nurse-reported operational failures at 14 hospitals. Twelve of the 14 obtained approval through expedited review and two went to the full board; the authors state that each expedited approval used category 7 of the expedited list.7 Sites took a mean of 45.1 business days to submit after receiving the materials, 14.3 days from submission to approval and 29.9 days from approval to study start.7 Added together, that is 89.3 days, and IRB review was 16% of it; preparing and submitting the application took 51%.

| IRB type | Sites | Days to submission | Days to approval | Days to study start |
|---|---|---|---|---|
| Academic IRB7 | 47 | 24.07 | 16.37 | 22.757 |
| Hospital-based IRB7 | 107 | 54.17 | 13.77 | 32.77 |
Swipe sideways to see every column.
The authors report no significant difference in approval times between academic and hospital IRBs.7 They attribute the similar review levels and timings to the nature of the study and to a protocol implementation kit with IRB templates, and sites could submit as soon as 2 days after receiving it. Two hospitals delayed submission for competing local demands; without them the mean time to submission was 33 days.7
A third paper gives context in numbers only. In a survey of 36 sites in a US multicentre critical care study, the median time to IRB approval was 30 days (interquartile range 14 to 54), ranging from 5 days to 5.5 months.12
What the two studies show
Together they show that review time is highly variable between boards, that requests for more information are associated with much longer approval times, and that in a multisite study with ready templates the application itself took longer than the review. Each paper describes one study in one setting, so the figures are examples and not national averages.
Single IRB Review for Multisite Studies
Since the 2018 revision, an institution in the United States that is engaged in cooperative research must rely on approval by a single IRB for the US portion of the research. The exceptions are research for which another law requires more than one review and research for which the supporting federal agency determines and documents that a single IRB is not appropriate.4 The compliance date for this provision is 20 January 2020; the general compliance date of the 2018 requirements is 21 January 2019.5 NIH applies its own single IRB policy to multisite non-exempt human subjects research that uses the same protocol, for grant applications due on or after 25 January 2018.13
The Canadian study illustrates the duplication that a single-review model aims to avoid. Each of the 16 boards had its own form: 4 sites needed only the board application, 9 needed one further hospital or administrative approval and 3 needed a third step.6 In the US study, 13 of 14 sites still ran an independent review of the standardized protocol; one site accepted the coordinating IRB approval through an investigator agreement.7

What to Put in Your IRB Submission
Build the submission around what the IRB must find under the regulation, and spend the most words where boards ask questions. In the Canadian study privacy and consent were the two major issues,6 and in the US critical care survey four sites cited IRB concern about waiver of consent as a major barrier.12
- 1State the research question, procedures and duration. The consent must explain the purposes, the expected duration and the procedures, so the protocol should define them first.14
- 2Show how risks are minimized and justified. The IRB must find risks minimized and reasonable in relation to anticipated benefits.10
- 3Explain who you will recruit and why. Selection of subjects must be equitable, with extra safeguards when subjects are vulnerable to coercion or undue influence.10
- 4Lead the consent with key information. Consent must begin with a concise and focused presentation of the information most likely to help a person decide, and it must not contain exculpatory language.14
- 5Document consent or request a waiver of documentation. Consent is normally documented with a signed form or a witnessed short form; the IRB decides on waivers.15,8
- 6Describe privacy and data protection. When appropriate, the plan needs adequate provisions to protect privacy and maintain confidentiality of data; in the US study, two expedited sites raised concerns about database security.10,7
Answering IRB Comments and Revisions
The IRB must notify you in writing whether it approves, disapproves or requires modifications. If it disapproves, it must give its reasons and let you respond in person or in writing.8 Under the expedited procedure the reviewers may not disapprove a study; only review at a convened meeting can do that.2 In the Canadian study, one board raised a new issue each time the previous one was answered, which required six responses.6 Answer every point in one organized response.
After Approval: Changes, Continuing Review and Records
Each IRB must have written procedures that ensure investigators conduct the research in accordance with the terms of the approval and that proposed changes are reviewed and approved by the IRB first, except when necessary to eliminate apparent immediate hazards to subjects.3 For research that needs convened review, continuing review is required at least once a year, but unless the IRB determines otherwise it is not required for research eligible for expedited review or for research that has reached data analysis or follow-up clinical data only.8 Unanticipated problems involving risks to subjects or others, and serious or continuing noncompliance, must be reported promptly under the IRB written procedures.3
How Editverse Analysed the Two Papers
Editverse read the full text of both papers from the PubMed Central XML on 3 November 2026 and confirmed the CC BY licence of each in the XML licence element. Numbers were taken from the Results and Tables of the papers, and the shares, ratio and total were computed by Editverse in R.6,7 Two details matter. Patel and colleagues give the mean time to approval as 14.3 days in the text and 14 days in the table; Editverse used the text value. Ezzat and colleagues describe the application steps differently in the abstract and in the Results; Editverse used the Results counts of 4, 9 and 3 sites, which add to 16.6,7
Need the Analysis Run or Checked? Consult Editverse
Editverse subject-matter experts work to COPE, ICMJE and GPP 2022 guidance, with institutional and country-specific ethics followed.
Editverse
Methodology Consultation
Is your study design ready for an IRB to read?
You send: your research question, draft design and sampling plan.
You get: three 45-minute sessions with PhD methodologists, a research design review with recommendations, and a written methodology framework document.
When: Before you draft the protocol, while the design can still change.
Methodology Consultation Package · $400
Editverse
Statistical Analysis
Approved and collecting data? Plan the analysis next.
You send: your data, research questions and preferred software.
You get: analysis in SPSS, R or STATA with annotated code or syntax, output files, an interpretation guide and publication-ready tables.
When: Your data are collected and the results section is not.
SPSS/R/STATA Statistical Analysis · $400
Editverse
Manuscript Writing
Study complete and approved? Write it up for a journal.
You send: your data, outline and references.
You get: a manuscript written by PhD-qualified subject matter experts, with technical review, statistical review and a plagiarism check; the service page states ICMJE and COPE compliance.
When: Your project is finished and the paper is not.
Manuscript Writing Services · $1,500
Free Research Tools from Editverse
- Free Sample Size Calculator: justify your sample size before you submit the protocol.
- Which Statistical Test Should I Use?: choose an analysis for the plan section.
- Free Effect Size Calculator: put effect sizes behind your power calculation.
Frequently Asked Questions
What are the three types of IRB review?
Under the Common Rule, research is exempt when the only involvement of human subjects falls in one of eight listed categories, eligible for expedited review when it involves no more than minimal risk and appears on the HHS list of nine categories, or reviewed at a convened meeting of the board. Some exempt categories involve limited IRB review.
How long does IRB approval take?
It varies by institution and by study. In one Canadian study across 16 hospitals the median time to final approval was 42 days, with a range of 4 to 443 days. In a US study at 14 hospitals the mean time from submission to IRB approval was 14.3 business days. In a survey of 36 sites in a US critical care study the median was 30 days, with a range of 5 days to 5.5 months. Ask your own IRB for its current calendar.
Is a single IRB required for multisite research?
Under the 2018 Common Rule, US institutions engaged in cooperative research must rely on a single IRB for the US portion, with a compliance date of 20 January 2020, unless a law requires more than one review or the funding agency determines and documents that a single IRB is not appropriate. NIH applies its own single IRB policy to multisite non-exempt human subjects research with the same protocol, for applications due on or after 25 January 2018.
Does exempt research still involve the IRB?
Exempt research is outside the policy requirements when it meets a listed category, but limited IRB review can or must be involved under four provisions. It can apply under 46.104(d)(2)(iii) and (d)(3)(i)(C), when identifiable information is recorded and an IRB conducts a limited review of privacy and confidentiality protections, and it is a condition of the broad consent exemptions at (d)(7) and (d)(8). Your IRB office can tell you how exemption decisions are made at your institution.
Can research with children or prisoners be exempt?
For research with children (subpart D), the exemptions at 46.104(d)(1), (4), (5), (6), (7) and (8) may be applied if their conditions are met. Survey, interview and educational test exemptions (d)(2)(i) and (ii) apply only to educational tests or observation of public behavior when the investigators do not participate, and (d)(2)(iii) may not be applied. For prisoners (subpart C) the exemptions do not apply, except for research aimed at a broader population that only incidentally includes prisoners.
What must an informed consent form contain?
Consent must begin with a concise and focused presentation of key information. The basic elements include a statement that the study is research, its purposes and expected duration, the procedures, foreseeable risks and benefits, alternatives where relevant, the extent of confidentiality, whom to contact, and a statement that participation is voluntary. Research with more than minimal risk must also explain compensation and treatment for injury.
What do IRBs question most often?
In the Canadian study of 16 hospitals, privacy and consent were the two major issues raised. In the US critical care survey, four sites cited IRB concern about waiver of consent as a major barrier to approval. Explain your consent process and your data protection plan clearly in the protocol.
Is continuing review required every year?
For research that requires convened review, continuing review is required at intervals appropriate to the risk and at least once a year, except as 46.109(f) allows. Unless the IRB determines otherwise, it is not required for research eligible for expedited review, for exempt research with limited IRB review, or for research that has reached data analysis or follow-up clinical data only. Check your approval letter.
References
- Electronic Code of Federal Regulations. 45 CFR 46.104, Exempt research (accessed 3 November 2026; eCFR current as of 30 October 2026). www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A/section-46.104
- Electronic Code of Federal Regulations. 45 CFR 46.110, Expedited review procedures for certain kinds of research involving no more than minimal risk, and for minor changes in approved research (accessed 3 November 2026; eCFR current as of 30 October 2026). www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A/section-46.110
- Electronic Code of Federal Regulations. 45 CFR 46.108, IRB functions and operations (accessed 3 November 2026; eCFR current as of 30 October 2026). www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A/section-46.108
- Electronic Code of Federal Regulations. 45 CFR 46.114, Cooperative research (accessed 3 November 2026; eCFR current as of 30 October 2026). www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A/section-46.114
- Electronic Code of Federal Regulations. 45 CFR 46.101, To what does this policy apply? Includes the compliance dates of 21 January 2019 and, for 46.114(b), 20 January 2020 (accessed 3 November 2026; eCFR current as of 30 October 2026). www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A/section-46.101
- Ezzat H, Ross S, von Dadelszen P, Morris T, Liston R, Magee LA; CPN Collaborative Group. Ethics review as a component of institutional approval for a multicentre continuous quality improvement project: the investigator’s perspective. BMC Health Serv Res. 2010;10:223. doi:10.1186/1472-6963-10-223. Licence CC BY 2.0 (PMC2921081). doi.org/10.1186/1472-6963-10-223
- Patel DI, Stevens KR, Puga F. Variations in institutional review board approval in the implementation of an improvement research study. Nurs Res Pract. 2013;2013:548591. doi:10.1155/2013/548591. Licence CC BY 3.0 (PMC3655662). doi.org/10.1155/2013/548591
- Electronic Code of Federal Regulations. 45 CFR 46.109, IRB review of research (accessed 3 November 2026; eCFR current as of 30 October 2026). www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A/section-46.109
- Electronic Code of Federal Regulations. 45 CFR 46.102, Definitions for purposes of this policy (accessed 3 November 2026; eCFR current as of 30 October 2026). www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A/section-46.102
- Electronic Code of Federal Regulations. 45 CFR 46.111, Criteria for IRB approval of research (accessed 3 November 2026; eCFR current as of 30 October 2026). www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A/section-46.111
- Food and Drug Administration and Office for Protection from Research Risks. Protection of human subjects: categories of research that may be reviewed by the institutional review board (IRB) through an expedited review procedure. Federal Register 1998;63(216):60353-60356 (9 November 1998). The list that 45 CFR 46.110(a) refers to. www.govinfo.gov/content/pkg/FR-1998-11-09/pdf/98-29748.pdf
- Polito CC, Cribbs SK, Martin GS, O’Keeffe T, Herr D, Rice TW, Sevransky JE. Navigating the institutional review board approval process in a multicenter observational critical care study. Crit Care Med. 2014;42(5):1105-1109. doi:10.1097/CCM.0000000000000133. PubMed abstract read; numbers cited only, no figures reused. pubmed.ncbi.nlm.nih.gov/24368345/
- National Institutes of Health, Office of Extramural Research. Single IRB for multi-site or cooperative research: policy and applicability (accessed 3 November 2026). grants.nih.gov/policy-and-compliance/policy-topics/human-subjects/single-irb-policy-multi-site-research
- Electronic Code of Federal Regulations. 45 CFR 46.116, General requirements for informed consent (accessed 3 November 2026; eCFR current as of 30 October 2026). www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A/section-46.116
- Electronic Code of Federal Regulations. 45 CFR 46.117, Documentation of informed consent (accessed 3 November 2026; eCFR current as of 30 October 2026). www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A/section-46.117
Related Reading
Editverse Research Team | Updated November 2026
